AzTrials
AzTrials

Colorectal SurgeryNCT06369194

POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol

An observational study of Colorectal Surgery and Critical Pathways, run by Grupo Español de Rehabilitación Multimodal at 36 sites in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The main objective of this study is to analyze the impact on five years survival of an enhanced recovery program (PRI) after radical surgery for colorectal cancer. As secondaries objectives, we propose to analyze comparing survival distributions between patient groups (ERAS/no ERAS) and the relationship between the… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Colorectal Surgery
Type of treatment
Surgery or procedure
How many people
847 participants
Where
36 sitesSpain
Study dates
14 Nov 2023to 15 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult patients (aged ≥18 years) undergoing colorectal elective surgery within an ERAS protocol (including patients with 0 compliance) in a participating hospital

Who may be able to join

  • All patients over 18 years of age who underwent elective colorectal cancer surgery in POWER1

Who cannot join

  • Non oncological surgery, refusal of the centers to participate.

Trial locations and contacts

36 sites in 1 country.

36 sites in 1 country

Spain36 sites
  • Hospital Universitario Araba

    Alava

  • Hospital Virgen de los Lirios de Alcoy

    Alcoy, Alicante

  • Hospital General Universitario de Alicante

    Alicante

  • Hospital Clínic Universitat de Barcelona

    Barcelona

  • Hospital del Mar

    Barcelona

  • Hospital Universitario Santa Creu i Sant Pau

    Barcelona

  • Hospital Universitario Vall d´Hebrón

    Barcelona

  • Hospital General Universitario de Castellón

    Castellon, Castellón

  • Hospital General Universitario de Ciudad Real

    Ciudad Real

  • Hospital General Universitario de Elche

    Elche, Alicante

  • Hospital de Galdakao-Usansolo

    Galdakao

  • Hospital de Igualada

    Igualada, Barcelona

  • Hospital Universitario de Gran Canaria Doctor Negrín

    Las Palmas

  • Hospital Universitario Insular de Gran Canaria

    Las Palmas de Gran Canaria

  • Hospital Universitario Rafael Méndez

    Lorca, Murcia

  • Hospital de La Princesa

    Madrid

  • Hospital Universitario 12 de Octubre

    Madrid

  • Hospital Universitario Infanta Leonor

    Madrid

  • Hospital Universitario Ramón y Cajal

    Madrid

  • Hospital Universitario San Carlos

    Madrid

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid

  • Hospital Costa del Sol

    Marbella, Málaga

  • Hospital Universitario de Móstoles

    Móstoles, Madrid

  • Hospital Universitario Central de Asturias

    Oviedo, Principality of Asturias

  • Complejo Hospitalario de Salamanca

    Salamanca

  • Hospital Universitario Donostia

    San Sebastián

  • Hospital de Sant Joan Despí Moisès Broggi

    Sant Joan d'Espi, Barcelona

  • Fundación Hospital del Espíritu Santo

    Santa Coloma de Gramenet, Barcelona

  • Hospital Universitario Virgen Macarena

    Seville

  • Hospital Nuestra Señora del Prado

    Talavera de la Reina, Toledo

  • Hospital Universitari Mútua Terrassa

    Terrassa, Barcelona

  • Consorcio Hospital General Unidersitario de Valencia

    Valencia

  • Hospital Clínico Universitario de Valencia

    Valencia

  • Hospital Clínico de Valladolid

    Valladolid

  • Hospital Universitario de Vic

    Vic, Barcelona

  • Hospital Universitario Miguel Server

    Zaragoza

Other trials in Spain

About this study

Official title: National Audit of Complications Following Lower Elective Gastrointestinal Surgery Within an Enhanced Recovery After Surgery Protocol

The main objective of this study is to analyze the impact on five years survival of an enhanced recovery program (PRI) after radical surgery for colorectal cancer. As secondaries objectives, we propose to analyze comparing survival distributions between patient groups (ERAS/no ERAS) and the relationship between the ERAS program and early incorporation into oncology therapies (RIOT).

It is proposed to review the medical records of oncology patients included in POWER 1 (as already foreseen in that study), with the aim of performing a 5-year follow-up.

To create comparable treatment and control groups, the Propensity Index method will be used. To study each variable, multivariate regression will be used. Kaplan-Meier will be used for survival and the log-rank test for comparisons. Significance will be considered if p <0.05 (two tails).

Read the detailed description

Study Data Five-year data will be collected from all eligible patients who have undergone elective colorectal surgery within the POWER1 protocol.

Only routine clinical data will be included and, when not available, the field will be left blank, e.g., patients lost to follow-up. Regional groups may supplement their basic data set with a very limited number of additional variables.

Data collection The data will be collected from CRFs collected in POWER1. The list of pseudo-anomized patients delivered at the time will be provided with the new variables to be completed by the centers.

Variables Overall mortality: The number and percentage of deaths occurred since the intervention until the end of the follow-up period.

Overall survival: patients alive from surgery to the last control. Disease-free survival: number of patients alive and without cancer recurrence from the intervention period until the end of follow-up.

Disease recurrence: detected by CT or FCC, from the day of the intervention until the end of the follow-up.

Date until start of adjuvant treatment: date between date of discharge and start of adjuvant treatment

Satistica analyse All regional and institutional level data will be anonymised prior to publication.

Continuous variables will be described as mean and standard deviation, if normally distributed, or median and inter-quartile range, if not normally distributed.

Comparisons of continuous variables will be performed using one-way ANOVA or Mann-Whitney test as appropriate.

Categorical variables will be described as proportions and will be compared using chi-square or Fisher's exact test.

Single-level and hierarchical multi-level logistic regression models will be constructed to identify factors independently associated with these outcomes and to adjust for differences in confounding factors.

Factors will be entered into the models based on their univariate relation to outcome (p<0.05), biological plausibility and low rate of missing data. A stepwise approach will be used to enter new terms.

Results of logistic regression will be reported as adjusted odds ratios (OR) with 95% confidence intervals. The models will be assessed through the use of sensitivity analyses to explore possible interacting factors and examine any effect on the results. A single final analysis is planned at the end of the study.

Survival analyzes will be performed using the Kaplan-Meier method for survival comparisons the log-rank test will be used. The effects will be considered significant if p <0.05.

Monitoring and audit The data collection documents will be audited to ensure that study activities are carried out in accordance with the protocol, good clinical practice and applicable regulatory requirements. In the participating hospitals, local study documents can be selected for local auditing. The quality of the data will be audited.

Limitations of the study Those of a prospective non-randomized study. Difficulty in recruiting patients for potential structural or multidisciplinary team problems. Inappropriate number of patients due loss of follow-up.

Being tested
Colorectal Surgery

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Colorectal SurgeryProcedure or surgery

    Postoperative Audit

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall Survival

    Patients alive from surgery to the last control

    Measured: 5 years

  2. Disease-free survival

    Number of patients alive and without cancer recurrence from the intervention period until the end of follow-up

    Measured: 5 years

  3. Time to disease recurrence

    Detected from the day of the intervention until the end of follow-up

    Measured: 5 years

  4. Time to return to intended oncologic treatment (RIOT)

    Date between discharged and adjuvant treatment

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2024
  2. Study start14 Nov 2023
  3. Primary completion15 Apr 2024 (estimated)
  4. Study completion15 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
847 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06369194
Sponsor's protocol ID
POWER5
Status last verified
Apr 2024
First submitted
12 Apr 2024
Last updated
19 Apr 2024
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

An observational study of Colorectal Surgery and Critical Pathways, run by Grupo Español de Rehabilitación Multimodal at 36 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall Survival (time frame: 5 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in